Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509740 | 1.00 | ALOX15 (0.50) | ALOX15BLMPMP22KMT2ADPP7 | |
| Hydrochloric Acid SCHEMBL5702744 | 0.98 | ALOX15 (0.48) | ALOX15BLMPMP22KMT2ADPP7 | |
| Hydrochloric Acid SCHEMBL4956521 | 0.98 | ALOX15 (0.48) | ALOX15BLMPMP22KMT2ADPP7 | |
| SCHEMBL6475399 | 0.85 | DPP7 (0.53) | DPP7ARG1DPP4DPP8FAP | |
| SCHEMBL6475403 | 0.85 | DPP7 (0.53) | DPP7ARG1DPP4DPP8FAP | |
| SCHEMBL6742082 | 0.79 | DPP7 (0.50) | ALOX15BLMPMP22KMT2ADPP7 | |
| SCHEMBL2583521 | 0.79 | TSHR (0.47) | ALOX15BLMPMP22KMT2AL3MBTL1 | |
| SCHEMBL1063045 | 0.78 | DPP7 (0.59) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL1063047 | 0.78 | DPP7 (0.59) | DPP7DPP4DPP8FAPDPP9 | |
| SCHEMBL6820919 | 0.78 | DPP7 (0.59) | DPP7DPP4DPP8FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528931-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR DECREASING THE RATE OF CHRONIC WEIGHT GAIN | PROSIDION LTD (GB) | 2008-05-07 | — | — | EP | claimed |
| CN-101095675-A | Dipeptidyl peptidase IV effectors | PROBIODRUG AG (GB) | 2008-01-02 | — | — | CN | claimed |
| US-20060287251-A1 | Combination therapy for glycaemic control | DEMUTH HANS-ULRICH | 2006-12-21 | — | — | US | claimed |
| CN-1845731-A | Combination therapy for glycaemic control | PROSIDION LTD (GB) | 2006-10-11 | — | — | CN | claimed |
| EP-1398030-B1 | Dipeptidyl peptidase IV effectors | PROSIDION LTD (GB) | 2006-09-06 | — | — | EP | claimed |
| EP-1663200-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | Prosidion Limited (GB) | 2006-06-07 | — | — | EP | claimed |
| US-20050203030-A1 | Novel effectors of dipeptidyl peptidase IV | PROSIDION LIMITED (GB) | 2005-09-15 | — | — | US | claimed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | claimed |
| WO-2005020983-A2 | COMBINATION THERAPY FOR GLYCAEMIC CONTROL | PROSIDION LTD. (GB) | 2005-03-10 | — | — | WO | claimed |
| JP-2004534836-A | — | — | 2004-11-18 | — | — | JP | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| EP-1416932-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | Probiodrug AG (DE) | 2004-05-12 | — | — | EP | claimed |
| EP-1399471-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | claimed |
| WO-2003015775-A1 | NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES FOR LOWERING BLOOD PRESSURE LEVELS | PROBIODRUG AG (DE) | 2003-02-27 | — | — | WO | claimed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | claimed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002595-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS AND THEIR USES AS ANTI-CANCER AGENTS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002596-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287251-A1 | Combination therapy for glycaemic control | IAPP, SLC5A2, GCG | ALOX15 2662/4885BLM 2284/4885PMP22 1004/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | ALOX15 2281/4885BLM 4376/4885PMP22 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.